Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Marshall

Showing results (71-80 of 90) with videos related to

Pageof 9
Sort By:
Pharmacogenomics|January 20, 2012
Semantically enabling pharmacogenomic data for the realization of personalized medicineMatthias Samwald, Adrien Coulet, Iker Huerga, et al.
Hematological Oncology|February 15, 2022
The safety and clinical effectiveness of rapid infusion with CT-P10 in patients with non-Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non-interventional post-authorization safety study in EuropeMark Bishton, Scott Marshall, Jatinder Harchowal, et al.
Pain|May 9, 2015
Predictors of the placebo analgesia response in randomized controlled trials of chronic pain: a meta-analysis of the individual data from nine industrially sponsored trialsLene Vase, Jan Vollert, Nanna B Finnerup, et al.
British Journal of Cancer|October 21, 2020
Epigenome-wide analysis reveals functional modulators of drug sensitivity and post-treatment survival in chronic lymphocytic leukaemiaTimothy M Barrow, Sirintra Nakjang, Fadhel Lafta, et al.
Cancers|January 11, 2022
Low BACH2 Expression Predicts Adverse Outcome in Chronic Lymphocytic LeukaemiaCarmela Ciardullo, Katarzyna Szoltysek, Peixun Zhou, et al.
British Journal of Haematology|February 1, 2011
Re-transplantation after bortezomib-based therapyCurly Morris, Gordon Cook, Matthew Streetly, et al.
Ejhaem|February 23, 2023
Real-world clinical effectiveness and safety of CT-P10 in patients with diffuse large B-cell lymphoma: An observational study in EuropeMark J Bishton, Gilles Salles, Camille Golfier, et al.
Oncotarget|November 6, 2015
PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemiaAshleigh Herriott, Susan J Tudhope, Gesa Junge, et al.
Drug Discovery Today|October 4, 2011
Empowering industrial research with shared biomedical vocabulariesLee Harland, Christopher Larminie, Susanna-Assunta Sansone, et al.
BMC Bioinformatics|May 12, 2007
Advancing translational research with the Semantic WebAlan Ruttenberg, Tim Clark, William Bug, et al.
Pageof 9

Showing results (71-80 of 90) with videos related to

Sort By:
Pageof 9
Pharmacogenomics|January 20, 2012
Semantically enabling pharmacogenomic data for the realization of personalized medicineMatthias Samwald, Adrien Coulet, Iker Huerga, et al.
Hematological Oncology|February 15, 2022
The safety and clinical effectiveness of rapid infusion with CT-P10 in patients with non-Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non-interventional post-authorization safety study in EuropeMark Bishton, Scott Marshall, Jatinder Harchowal, et al.
Pain|May 9, 2015
Predictors of the placebo analgesia response in randomized controlled trials of chronic pain: a meta-analysis of the individual data from nine industrially sponsored trialsLene Vase, Jan Vollert, Nanna B Finnerup, et al.
British Journal of Cancer|October 21, 2020
Epigenome-wide analysis reveals functional modulators of drug sensitivity and post-treatment survival in chronic lymphocytic leukaemiaTimothy M Barrow, Sirintra Nakjang, Fadhel Lafta, et al.
Cancers|January 11, 2022
Low BACH2 Expression Predicts Adverse Outcome in Chronic Lymphocytic LeukaemiaCarmela Ciardullo, Katarzyna Szoltysek, Peixun Zhou, et al.
British Journal of Haematology|February 1, 2011
Re-transplantation after bortezomib-based therapyCurly Morris, Gordon Cook, Matthew Streetly, et al.
Ejhaem|February 23, 2023
Real-world clinical effectiveness and safety of CT-P10 in patients with diffuse large B-cell lymphoma: An observational study in EuropeMark J Bishton, Gilles Salles, Camille Golfier, et al.
Oncotarget|November 6, 2015
PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemiaAshleigh Herriott, Susan J Tudhope, Gesa Junge, et al.
Drug Discovery Today|October 4, 2011
Empowering industrial research with shared biomedical vocabulariesLee Harland, Christopher Larminie, Susanna-Assunta Sansone, et al.
BMC Bioinformatics|May 12, 2007
Advancing translational research with the Semantic WebAlan Ruttenberg, Tim Clark, William Bug, et al.
Pageof 9